The Intensive Care Platform Trial
Launched by ANDERS PERNER · Oct 30, 2024
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
The Intensive Care Platform Trial (INCEPT) is a research study designed to improve the treatment of critically ill patients in intensive care units (ICUs). The trial aims to evaluate the effectiveness of various treatments used in ICUs, as many patients face serious health challenges and some may not benefit from the treatments they receive. INCEPT will gather and analyze data continuously, allowing researchers to learn from the results and make better decisions about patient care. This approach means the trial can adapt to new treatments over time and involve patients and their families in the process, ensuring that their perspectives are considered.
To participate in this trial, patients must be adults (18 years or older) who are admitted to the ICU for urgent medical reasons, such as after an emergency surgery or due to complications from previous surgeries. Participants can expect to be part of a flexible study that aims to improve outcomes not only for themselves but also for future ICU patients. By joining the INCEPT trial, patients will contribute to research that seeks to identify effective and safe treatments, ultimately improving the overall quality of care in intensive care settings.
Gender
ALL
Eligibility criteria
- • The general eligibility criteria below apply to INCEPT as a whole and thus to all domains. Domains may impose domain-specific eligibility criteria that restrict the population eligible for that domain further, but domains are not allowed to broaden the general eligibility criteria. Domain-specific eligibility criteria always apply to all arms in a domain.
- PLATFORM INCLUSION CRITERIA:
- • Adult patient (≥18 years old) acutely admitted to the ICU. This includes ICU admissions after emergency surgery, unplanned ICU admissions after elective surgery, and prolonged ICU admissions due to complications after elective surgery (i.e., admissions occurring or being prolonged due to an unexpected, worsened condition, but excluding planned ICU admissions after elective surgery without clinical deterioration).
- • Eligible for at least one active domain.
- PLATFORM EXCLUSION CRITERIA:
- • Informed consent following inclusion expected to be unobtainable (e.g., known previous objections to participation).
- • Patient is under coercive measures (e.g., ongoing involuntary hospital stay or under the jurisdiction of correctional authorities).
- • Patients who have previously been included in INCEPT may only be included again during new ICU admissions but may only be randomised to domains in which they have not previously been randomised.
- DOMAIN-SPECIFIC ELIGIBLE CRITERIA:
- • Each domain may have additional eligibility criteria. Refer to the study website for more information (www.incept.dk).
About Anders Perner
Anders Perner is a distinguished clinical trial sponsor renowned for his commitment to advancing medical research and improving patient outcomes. With a robust background in critical care medicine, he leads initiatives that focus on innovative trial designs and the integration of cutting-edge technologies in clinical studies. His collaborative approach fosters partnerships between academic institutions and industry stakeholders, ensuring rigorous scientific methodologies are applied to address pressing healthcare challenges. Under his guidance, clinical trials are conducted with an emphasis on ethical standards, patient safety, and the generation of high-quality evidence to inform clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Aalborg, , Denmark
Aabenraa, , Denmark
Aarhus, , Denmark
Aarhus, , Denmark
Copenhagen, , Denmark
Copenhagen, , Denmark
Copenhagen, , Denmark
Herlev, , Denmark
Herning, , Denmark
Hillerød, , Denmark
Hvidovre, , Denmark
Kolding, , Denmark
Køge, , Denmark
Nykøbing Falster, , Denmark
Odense, , Denmark
Randers, , Denmark
Slagelse, , Denmark
Viborg, , Denmark
Patients applied
Trial Officials
Anders Perner, Professor
Study Chair
Copenhagen University Hospital - Rigshospitalet, Department of Intensive Care
Anders Granholm, MD
Principal Investigator
Copenhagen University Hospital - Rigshospitalet, Department of Intensive Care
Morten H Moeller, Professor
Principal Investigator
Copenhagen University Hospital - Rigshospitalet, Department of Intensive Care
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported